The first large and comprehensive study of the genetics of a common lung cancer has found that more than half the tumors from that cancer have mutations that might be treated by new drugs that are already in the pipeline or that could be easily developed. Matthew Meyerson, HMS professor of pathology and Bruce Evan Johnson, HMS professor of medicine, both of Dana-Farber Cancer Institute, are authors on the paper.
